Acute myeloid leukemia: Conventional cytogenetics, FISH, and moleculocentric methodologies

Clinics in Laboratory Medicine

Volumn 31, Issue 4, 2011, Pages 659-686

  Morrissette, Jennifer J D ^a   Bagg, Adam ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

AML; Classification; Cytogenetics; FISH; Molecular genetic

Indexed keywords

ALKYLATING AGENT; CBL PROTEIN; CCAAT ENHANCER BINDING PROTEIN ALPHA; CHLORAMBUCIL; DNA METHYLTRANSFERASE 3A; FLT3 LIGAND; GYRASE INHIBITOR; MELPHALAN; MIXED LINEAGE LEUKEMIA PROTEIN; NUCLEOPHOSMIN; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN P53; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR RUNX1; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ASXL1 GENE; CBL GENE; CEBPA GENE; CELL CYCLE PHASE; CHROMOSOME 1; CHROMOSOME 11; CHROMOSOME 11Q; CHROMOSOME 13P; CHROMOSOME 13Q; CHROMOSOME 15; CHROMOSOME 16; CHROMOSOME 16P; CHROMOSOME 17; CHROMOSOME 21P; CHROMOSOME 21Q; CHROMOSOME 22; CHROMOSOME 22P; CHROMOSOME 3Q; CHROMOSOME 6; CHROMOSOME 8; CHROMOSOME 9; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CHROMOSOME DELETION 22Q11; CHROMOSOME REARRANGEMENT; CHROMOSOME TRANSLOCATION; CYTOGENETICS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DNA SEQUENCE; DNMT3A GENE; DOWN SYNDROME; FLT3 GENE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE DISRUPTION; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENE FUSION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; IDH1 GENE; IDH2 GENE; KARYOTYPING; KIT GENE; KRAS GENE; MLL GENE; MOLECULAR GENETICS; MOLECULAR MECHANICS; MONOSOMAL KARYOTYPE; MONOSOMY 5; MONOSOMY 7; MYELODYSPLASTIC SYNDROME; NPM1 GENE; NRAS GENE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; RNA SPLICING; RUNX1 GENE; TET2 GENE; TP53 GENE; TRISOMY 8; WT1 GENE; X CHROMOSOME; Y CHROMOSOME;

AGED; CHILD; CHROMOSOME ABERRATIONS; CYTOGENETICS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, MYELOID, ACUTE; MYELODYSPLASTIC SYNDROMES;

EID: 82355181581     PISSN: 02722712     EISSN: 15579832     Source Type: Journal    
DOI: 10.1016/j.cll.2011.08.006     Document Type: Review

References (93)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96.
2. Grimwade D., Hills R.K., Moorman A.V., et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010, 116:354-365. National Cancer Research Institute Adult Leukaemia Working Group.
3. Arber D.A., Brunning R.D., Le Beau M.M., et al. Acute myeloid leukaemia with recurrent genetic abnormalities. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008, 110-123. IARC, Lyon. S.H. Swerdlow, E. Campo, N.L. Harris (Eds.).
4. Gilliland D.G. Hematologic malignancies. Curr Opin Hematol 2001, 8:189-191.
5. Reilly J.T. Pathogenesis of acute myeloid leukaemia and inv(16)(p13;q22): a paradigm for understanding leukaemogenesis?. Br J Haematol 2005, 128:18-34.
6. Betts D.R., Ammann R.A., Hirt A., et al. The prognostic significance of cytogenetic aberrations in childhood acute myeloid leukaemia: a study of the Swiss Paediatric Oncology Group (SPOG). Eur J Haematol 2007, 78:468-476.
7. von Neuhoff C., Reinhardt D., Sander A., et al. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. J Clin Oncol 2010, 28:2682-2689.
8. Berger R, Bernheim A, Ochoa-Noguera ME, et al. Prognostic significance of chromosomal abnormalities in acute nonlymphocytic leukemia: a study of 343 patients. Cancer Genet Cytogenet 987;28:293-9.
9. Samuels B.L., Larson R.A., Le Beau M.M., et al. Specific chromosomal abnormalities in acute nonlymphocytic leukemia correlate with drug susceptibility in vivo. Leukemia 1988, 2:79-83.
10. Keating M.J., Smith T.L., Kantarjian H., et al. Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome. Leukemia 1988, 2:403-412.
11. Fenaux P., Preudhomme C., Lai J.L., et al. Cytogenetics and their prognostic significance in acute myeloid leukaemia: a report on 283 cases. Br J Haematol 1989, 73:61-67.
12. Marosi C., Köller U., Koller-Weber E., et al. Prognostic impact of karyotype and immunologic phenotype in 125 adult patients with de novo AML. Cancer Genet Cytogenet 1992, 61:14-25.
13. Dastugue N., Payen C., Lafage-Pochitaloff M., et al. Prognostic significance of karyotype in de novo adult myeloid leukemia. Leukemia 1995, 9:1491-1498.
14. Damm F., Heuser M., Morgan M., et al. Integrative prognostic risk score in acute myeloid leukemia with normal karyotype. Blood 2011, [Epub ahead of print].
15. Tavor S., Rothman R., Golan T., et al. Predictive value of TP53 fluorescence in situ hybridization in cytogenetic subgroups of acute myeloid leukemia. Leuk Lymphoma 2011, 52:642-647.
16. Fröhling S., Kayser S., Mayer C., et al. Diagnostic value of fluorescence in situ hybridization for the detection of genomic aberrations in older patients with acute myeloid leukemia. Haematologica 2005, 90:194-199. AML Study Group Ulm.
17. Vance G.H., Kim H., Hicks G.A., et al. Utility of interphase FISH to stratify patients into cytogenetic risk categories at diagnosis of AML in an Eastern Cooperative Oncology Group (ECOG) clinical trial (E1900). Leuk Res 2007, 31:605-609.
18. Volpi E.V., Bridger J.M. FISH glossary: an overview of the fluorescence in situ hybridization technique. Biotechniques 2008, 45:385-386.
19. King R.L., Naghashpour M., Watt C.D., et al. A comparative analysis of molecular genetic and conventional cytogenetic detection of diagnostically important translocations in over 400 cases of acute leukemia, highlighting the frequency of false negative conventional cytogenetics. Am J Clinic Path 2011, 135:921-928.
20. Speck N.A., Gilliland D.G. Core-binding factors in haematopoiesis and leukaemia. Nat Rev Cancer 2002, 2:502-513.
21. Harrison C.J., Hills R.K., Moorman A.V., et al. Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. J Clin Oncol 2010, 28:2674-2681.
22. Acute myelogenous leukemia with an 8;21 translocation; a report on 148 cases from the Groupe Francais de Cytogenetique Hematologique. Cancer Genet Cytogenet 1990, 44:169-179. Groupe Francais de Cytogenetique Hematologique.
23. Huang L., Abruzzo L.V., Valbuena J.R., et al. Acute myeloid leukemia associated with variant t(8;21) detected by conventional cytogenetic and molecular studies: a report of four cases and review of the literature. Am J Clin Pathol 2006, 125:267-272.
24. Elagib K.E., Goldfarb A.N. Oncogenic pathways of AML1-ETO in acute myeloid leukemia: multifaceted manipulation of marrow maturation. Cancer Lett 2007, 251:179-186.
25. Wiemels J.L., Xiao Z., Buffler P.A., et al. In utero origin of t(8;21) AML1-ETO translocations in childhood acute myeloid leukemia. Blood 2002, 99:3801-3805.
26. Jurlander J., Caligiuri M.A., Ruutu T., et al. Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia. Blood 1996, 88:2183-2191.
27. Miyamoto T., Nagafuji K., Akashi K., et al. Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia. Blood 1996, 87:4789-4796.
28. Ommen H.B., Ostergaard M., Yan M., et al. Persistent altered fusion transcript splicing identifies RUNX1-RUNX1T1+ AML patients likely to relapse. Eur J Haematol 2010, 84:128-132.
29. Paschka P., Marcucci G., Ruppert A.S., et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol 2006, 24:3904-3911.
30. Schnittger S., Kohl T.M., Haferlach T., et al. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood 2006, 107:1791-1799.
31. Pollard J.A., Alonzo T.A., Gerbing R.B., et al. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood 2010, 115:2372-2379.
32. Care R.S., Valk P.J., Goodeve A.C., et al. Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br J Haematol 2003, 121:775-777.
33. Paschka P., Marcucci G., Ruppert A.S., et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol 2006, 24:3904-3911. Cancer and Leukemia Group B.
34. Boissel N., Leroy H., Brethon B., et al. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia 2006, 20:965-970.
35. Paschka P. Core binding factor acute myeloid leukemia. Semin Oncol 2008, 35:410-417.
36. Huang G., Shigesada K., Wee H.J., et al. Molecular basis for a dominant inactivation of RUNX1/AML1 by the leukemogenic inversion 16 chimera. Blood 2004, 103:3200-3207.
37. Rowley J.D. Identification of a translocation with quinacrine fluorescence in a patient with acute leukaemia. Ann. Genet 1973, 16:109-112.
38. Kent W.J., Sugnet C.W., Furey T.S., et al. The human genome browser at UCSC. Genome Res 2002, 12:996-1006. Accessed August 15, 2011. http://genome.ucsc.edu/cgi-bin/hgTracks?hgHubConnect.destUrl=%2Fcgi-%09bin%2FhgTracks%26clade=mammal%26org=Human%26db=hg19%26position=chr15%3A74287014-%0974340153%26hgt.suggest=PML%26hgt.suggestTrack=knownGene%26Submit=submit%26hgsid=21192596%095%26hgt.newJQuery=1%26knownGene=pack.
39. Beitinjaneh A., Jang S., Roukoz H., et al. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations in acute promyelocytic leukemia: a systematic review. Leuk Res 2010, 34:831-836.
40. Krauter J., Wagner K., Schäfer I., et al. Prognostic factors in adult patients up to 60 years old with acute myeloid leukemia and translocations of chromosome band 11q23: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol 2009, 27:3000-3006.
41. Raimondi S.C., Chang M.N., Ravindranath Y., et al. Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative pediatric oncology group study-POG 8821. Blood 1999, 94:3707-3716.
42. Lugthart S., Gröschel S., Beverloo H.B., et al. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. J Clin Oncol 2010, 28:3890-3898.
43. Stark B., Jeison M., Gabay L.G., et al. Classical and molecular cytogenetic abnormalities and outcome of childhood acute myeloid leukaemia: report from a referral centre in Israel. Br J Haematol 2004, 126:320-337.
44. Slovak M.L., Gundacker H., Bloomfield C.D., et al. A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignancies. Leukemia 2006, 20:1295-1297.
45. Thiede C., Steudel C., Mohr B., et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002, 12:4326-4335.
46. Dastugue N., Lafage-Pochitaloff M., Pagès M.P., et al. Cytogenetic profile of childhood and adult megakaryoblastic leukemia (M7): a study of the Groupe Français de Cytogénétique Hématologique (GFCH). Blood 2002, 100:618-626.
47. Arber D.A., Brunning R.D., Le Beau M.M., et al. Acute myeloid leukaemia with myelodysplasia-related changes. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008, 124-126. IARC, Lyon. S.H. Swerdlow, E. Campo, N.L. Harris (Eds.).
48. Falini B., Macijewski K., Weiss T., et al. Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1). Blood 2010, 115:3776-3786.
49. Ebert B.L. Genetic deletions in AML and MDS. Best Pract Res Clin Haematol 2010, 23:457-461.
50. Gondek L.P., Tiu R., O'Keefe C.L., et al. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood 2008, 111:1534-1542.
51. Starczynowski D.T., Kuchenbauer F., Argiropoulos B., et al. Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat Med 2009, 16:49-58.
52. Johansson B, Harrison CJ. Acute myeloid leukemia. In: Heim S, Mitelman F, editors. Cancer cytogenetics, chromosomal and molecular genetic aberrations in tumor cells. Hoboken (NJ): John Wiley & Sons; p. 45-139.
53. Curtiss N.P., Bonifas J.M., Lauchle J.O., et al. Isolation and analysis of candidate myeloid tumor suppressor genes from a commonly deleted segment of 7q22. Genomics 2005, 85:600-607.
54. Vardiman J.W., Arber D.A., Brunning R.D., et al. Acute myeloid leukaemia with recurrent genetic abnormalities. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008, 127-129. IARC, Lyon. S.H. Swerdlow, E. Campo, N.L. Harris (Eds.).
55. Gustafson S.A., Lin P., Chen S.S., et al. Therapy-related acute myeloid leukemia with t(8;21) (q22;q22) shares many features with de novo acute myeloid leukemia with t(8;21)(q22;q22) but does not have a favorable outcome. Am J Clin Pathol 2009, 131:647-655.
56. Qian Z., Joslin J.M., Tennant T.R., et al. Cytogenetic and genetic pathways in therapy-related acute myeloid leukemia. Chem Biol Interact 2010, 184:50-57.
57. Baumann I., Niemeyer C.M., Brunning R.D., et al. Myeloid proliferations related to Down syndrome. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008, 124-126. IARC, Lyon. S.H. Swerdlow, E. Campo, N.L. Harris (Eds.).
58. Breems D.A., Van Putten W.L., De Greef G.E., et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol 2008, 26:4791-4797.
59. Medeiros B.C., Othus M., Fang M., et al. Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. Blood 2010, 116:2224-2228.
60. Breems D.A., Löwenberg B. Acute myeloid leukemia with monosomal karyotype at the far end of the unfavorable prognostic spectrum. Haematologica 2011, 96:491-493.
61. Broeker P.L., Super H.G., Thirman M.J., et al. Distribution of 11q23 breakpoints within the MLL breakpoint cluster region in de novo acute leukemia and in treatment-related acute myeloid leukemia: correlation with scaffold attachment regions and topoisomerase II consensus binding sites. Blood 1996, 87:1912-1922.
62. Schoch C., Schnittger S., Klaus M., et al. AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. Blood 2003, 102:2395-2402.
63. Balgobind B.V., Raimondi S.C., Harbott J., et al. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood 2009, 114:2489-2496.
64. Haferlach T., Kohlmann A., Klein H.U., et al. AML with translocation t(8;16)(p11;p13) demonstrates unique cytomorphological, cytogenetic, molecular and prognostic features. Leukemia 2009, 23:934-943.
65. Smith M.L., Hills R.K., Grimwade D. Independent prognostic variables in acute myeloid leukaemia. Blood Rev 2011, 25:39-51.
66. Reaman G.H., Smith F.O. Childhood leukemia: a practical handbook 2011, Springer Verlag, Heidelberg (Germany).
67. Pui C.H., Carroll W.L., Meshinchi S., et al. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol 2011, 29:551-565.
68. Watt C.D., Bagg A. Molecular diagnosis of acute myeloid leukemia. Expert Rev Mol Diagn 2010, 10:993-1012.
69. Marcucci G., Haferlach T., Döhner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol 2011, 29:475-486.
70. Falini B., Martelli M.P., Bolli N. Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?. Blood 2011, 117:1109-1120.
71. Wertheim G., Bagg A. Nucleophosmin (NPM1) mutations in acute myeloid leukemia: an ongoing (cytoplasmic) tale of dueling mutations and duality of molecular genetic testing methodologies. J Mol Diagn 2008, 10:198-202.
72. Taskesen E., Bullinger L., Corbacioglu A. Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood 2011, 117:2469-2475.
73. Döhner K., Schlenk R.F., Habdank M., et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 2005, 106:3740-3746.
74. Breitenbuecher F., Schnittger S., Grundler R. Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor. Blood 2009, 113:4074-4077.
75. Gale R.E., Hills R., Pizzey A.R., et al. Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. Blood 2005, 106:3768-3776.
76. Schnittger S., Kohl T.M., Haferlach T., et al. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood 2006, 107:1791-1799.
77. Basecke J., Whelan J.T., Griesinger F., et al. The MLL partial tandem duplication in acute myeloid leukaemia. Br J Haematol 2006, 135:438-449.
78. Chandra P., Luthra R., Zuo Z., et al. Acute myeloid leukemia with t(9;11)(p21-22;q23): common properties of dysregulated ras pathway signaling and genomic progression characterize de novo and therapy-related cases. Am J Clin Pathol 2010, 133:686-693.
79. Raghavan M., Smith L.L., Lillington D.M., et al. Segmental uniparental disomy is a commonly acquired genetic event in relapsed acute myeloid leukemia. Blood 2008, 112:814-821.
80. Parkin B., Erba H., Ouillette P., et al. Acquired genomic copy number aberrations and survival in adult acute myelogenous leukemia. Blood 2010, 116:4958-4967.
81. Tiu R.V., Gondek L.P., O'Keefe C.L., et al. New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid leukemia. J Clin Oncol 2009, 27:5219-5226.
82. Bullinger L., Kronke J., Schon C., et al. Identification of acquired copy number alterations and uniparental disomies in cytogenetically normal acute myeloid leukemia using high-resolution single nucleotide polymorphism analysis. Leukemia 2010, 24:438-449.
83. Bullinger L., Rücker F.G., Kurz S., et al. Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia. Blood 2007, 110:1291-1300.
84. Metzeler K.H., Hummel M., Bloomfield C.D., et al. An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood 2008, 112:4193-4201. Cancer and Leukemia Group B; German AML Cooperative Group.
85. Radmacher M.D., Marcucci G., Ruppert A.S., et al. Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study. Blood 2006, 108:1677-1683.
86. Chen J., Odenike O., Rowley J.D. Leukaemogenesis: more than mutant genes. Nat Rev Cancer 2008, 10:23-36.
87. Ley T.J., Ding L., Walter M.J., et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010, 363:2424-2433.
88. Yan X.J., Xu J., Gu Z.H., et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia [Epub ahead of print]. Nat Genet 2011.
89. Garzon R., Volinia S., Liu C.G., et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukaemia. Blood 2008, 111:3183-3189.
90. Marcucci G., Mrózek K., Radmacher M.D., et al. The prognostic and functional role of microRNAs in acute myeloid leukemia. Blood 2011, 117:1121-1129.
91. Ley T.J., Mardis E.R., Ding L., et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 2008, 456:66-72.
92. Greif P.A., Eck S.H., Konstandin N.P., et al. Identification of recurring tumor-specific somatic mutations in acute myeloid leukemia by transcriptome sequencing [Epub ahead of print]. Leukemia 2011.
93. Ng S.B., Turner E.H., Robertson P.D., et al. Targeted capture and massively parallel sequencing of 12 human exomes. Nature 2009, 461:272-276.